Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial
Crossref DOI link: https://doi.org/10.1007/s10549-016-4075-6
Published Online: 2016-12-22
Published Print: 2017-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yamamoto, Daigo
Sato, Nobuaki
Rai, Yoshiaki
Yamamoto, Yutaka
Saito, Mitsue
Iwata, Hiroji
Masuda, Norikazu
Oura, Shoji
Watanabe, Junichiro
Hattori, Satoshi
Matsuura, Yoshimasa
Kuroi, Katsumasa
License valid from 2016-12-22